Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,614 | 4 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma Global Development | $1,614 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,614 | 4 | Astellas Pharma Global Development ($1,614) |
All Payment Transactions
4 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/20/2023 | Astellas Pharma Global Development | Cresemba (Drug) | — | Cash or cash equivalent | $338.44 | Research |
| Study: A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants • Category: Infectious Diseases | ||||||
| 10/20/2023 | Astellas Pharma Global Development | Cresemba (Drug) | — | Cash or cash equivalent | $203.47 | Research |
| Study: A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants • Category: Infectious Diseases | ||||||
| 08/18/2023 | Astellas Pharma Global Development | Cresemba (Drug) | — | Cash or cash equivalent | $851.23 | Research |
| Study: A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants • Category: Infectious Diseases | ||||||
| 04/19/2023 | Astellas Pharma Global Development | Cresemba (Drug) | — | Cash or cash equivalent | $221.08 | Research |
| Study: A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants • Category: Infectious Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants | Astellas Pharma Global Development | $1,614 | 4 |
About Dr. Benjamin Hanisch, MD
Dr. Benjamin Hanisch, MD is a Pediatrics healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2008. The National Provider Identifier (NPI) number assigned to this provider is 1932364809.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Hanisch, MD has received a total of $1,614 in payments from pharmaceutical and medical device companies, with $1,614 received in 2023. These payments were reported across 4 transactions from 1 company. The most common payment nature is "" ($1,614).
Practice Information
- Specialty Pediatrics
- Location Washington, DC
- Active Since 07/21/2008
- Last Updated 07/23/2014
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1932364809
Products in Payments
- Cresemba (Drug) $1,614
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Washington
Helen Thackray, Md, MD
Pediatrics — Payments: $4.6M
Dr. Ikechi Nnawuchi
Pediatrics — Payments: $654,155
Michael Guerrera, Md, MD
Pediatrics — Payments: $326,304
Brenda Martin, Np, NP
Pediatrics — Payments: $102,882
David Nelson
Pediatrics — Payments: $22,971
Gary Kupfer
Pediatrics — Payments: $22,067